Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and postabsorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice
The request follows an extensive FDA safety review examining nearly 100 placebo-controlled clinical trials involving more than 106,000 patients
Novo Nordisks Competitive Response: Anticipating generic competition, Novo Nordisk is preparing to launch new branded versions of semaglutide under different names that are medically identical to Ozempic and Wegovy but lower-priced
Nonalcoholic fatty liver disease and insulin resistance in children
What stands out in this years data is the gap between how visible GLP-1s have become and how willing people are to talk about using them, said Adam Wolfberg, MD, Chief Medical Officer at Virta Health
Compounded Medication Safety Notice: The FDA has identified concerns involving compounded GLP-1 products, including dosing errors, improper storage during shipping, fraudulent products, adverse-event reports, and semaglutide salt forms
